AIDA: A Potential Drug Target and Biomarker for Various Diseases

Target Name: AIDA

NCBI ID: G64853

AIDA

AIDA: A Potential Drug Target and Biomarker for Various Diseases

AIDA (AIDA\\_HUMAN) is a protein that is expressed in various tissues of the human body, including the brain, heart, kidneys, and liver. It is a member of the AIDA family, which includes several related proteins that play important roles in the regulation of cellular processes such as cell adhesion, migration, and survival.

One of the unique features of AIDA is its ability to interact with several different signaling pathways, including TGF-β, NF-kappa-B, and PI3K/AKT. This makes it an attractive target for drug development, as it can be used to treat a wide range of diseases and conditions.

One of the key benefits of AIDA is its potential to act as a biomarker for several types of cancer. AIDA has been shown to be highly expressed in various types of cancer, including breast, ovarian, and colorectal cancer. Additionally, it has been shown to be involved in the development and progression of several types of cancer, including neurodegenerative diseases and autoimmune disorders.

Another potential use of AIDA as a drug target is its role in modulating inflammation. AIDA has been shown to play a key role in the regulation of immune responses and has been implicated in the development of several inflammatory diseases, including rheumatoid arthritis and multiple sclerosis.

In addition to its potential as a drug target and biomarker, AIDA is also of interest to researchers as a potential therapeutic target for a wide range of diseases and conditions. For example, AIDA has been shown to be involved in the regulation of several cellular processes that are important for brain development and function, including cell adhesion, migration, and survival. This makes it an attractive target for treatments of neurodegenerative diseases, including Alzheimer's disease, Parkinson's disease, and Huntington's disease.

In conclusion, AIDA is a protein that has significant potential as a drug target and biomarker for a wide range of diseases and conditions. Its ability to interact with multiple signaling pathways and its expression in various tissues make it an attractive target for research and treatment. Further research is needed to fully understand the role of AIDA in cellular processes and its potential as a therapeutic target.

Protein Name: Axin Interactor, Dorsalization Associated

Functions: Acts as a ventralizing factor during embryogenesis. Inhibits axin-mediated JNK activation by binding axin and disrupting axin homodimerization. This in turn antagonizes a Wnt/beta-catenin-independent dorsalization pathway activated by AXIN/JNK-signaling (By similarity)

The "AIDA Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about AIDA comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets